Rare and Genetic Kidney Disease DD Summit on August 18-20, 2026 in Boston, United States

The 6th Rare and Genetic Kidney Disease Drug Development Summit is the industry's only meeting dedicated exclusively to advancing therapies across IgAN, FSGS, ADPKD, Alport syndrome, C3G, and related renal indications. Bringing together leaders from biopharma, academia, and patient advocacy, this summit spans discovery through commercialization to support smarter, faster decision-making across kidney disease pipelines.

As competition intensifies in rare and genetic kidney disease drug development, companies are under increasing pressure to differentiate assets, generate robust clinical evidence, and accelerate timelines to patients. Accelerated approval pathways have fundamentally reshaped how teams approach target evaluation, surrogate endpoint selection, and trial design within small, heterogeneous patient populations. With more programs progressing into mid- and late-stage development than ever before, the stakes for getting these decisions right have never been higher.

At the same time, persistent challenges in patient recruitment, uncertainty around clinically meaningful surrogate endpoints, and incomplete mechanistic understanding continue to slow trials and increase risk. To move the field forward, teams must adopt more precise patient stratification strategies, build stronger translational models, and optimize trial designs that balance scientific rigor with operational feasibility.

This year's summit convenes experts from organizations advancing approved and late-stage therapies, including Novartis, Calliditas, and Travere Therapeutics, to share real-world data, pressure-test development strategies, and benchmark approaches across the renal landscape. Attendees will gain practical insights into novel target validation, endpoint selection, and patient-focused trial design that can be applied directly to ongoing and future programs.

Join the community shaping the next generation of kidney disease therapies and leave with actionable strategies to advance promising assets from discovery to patients.

URLs:

Website: https://go.evvnt.com/3590343-0?pid=10008

Tickets: https://go.evvnt.com/3590343-2?pid=10008

Brochure: https://go.evvnt.com/3590343-3?pid=10008

Prices:

Drug Developer Pricing - Conference + 3 Workshops: USD 4397.00,

Drug Developer Pricing - Conference Only: USD 3099.00,

Academic Pricing - Conference + 3 Workshops: USD 3797.00,

Academic Pricing - Conference Only: USD 2699.00,

Service Provider Pricing - Conference + 3 Workshops: USD 5297.00,

Service Provider Pricing - Conference Only: USD 3799.00

Speakers: Savithri Kota, Director, Precision Nephrology, Bayer, Jennifer McKenzie, Senior Clinical Program Leader, Boehringer Ingelheim, Srini Srinivas, Senior Medical, Director Novartis, Kristin Van Goor, Executive Director and US Head, Global Regulatory Policy and Innovation, Takeda, Nitender Goyal, Senior Director Clinical Research, Alnylam Pharmaceuticals, Sherrita Dorsey, US Head Patient and Professional Advocacy, Amicus Therapeutics, Eli Khankin, Executive Director, Apellis Pharmaceuticals, Rowland Elwell, Executive Medical Director, Nephrology Calliditas, Giorgia Jurisic Snijder, Director, Disease Area Expert, Rare Renal, CSL, Gabriela Alperovich, Executive Director, Medical, Cardiovascular and Renal, Global Clinical Lead, CSL, Danielle Branch, Director, Patient Advocacy and Community Engagement, Maze Therapeutics, Adele Rowley, Chief Scientific Officer, Mironid, Jeff Sands, Chief Medical Officer, NephroDI, Julie Lin, Senior Vice President, Clinical Development and Drug Safety/ Pharmacovigilance, Travere Therapeutics, Joshua Waitzman, Senior Medical Director, Vera Therapeutics, Manish Maski, Executive Director - Global Medical Affairs and Nephrology Lead, Vertex Pharmaceuticals, Thomas Miller, SVP, Head of Research, Walden Biosciences, Sean Eddy, Associate Research Scientist, University of Michigan, Howard Trachtman, Adjunct Professor, University of Michigan, Richard Gilbert, Professor of Medicine, University of Toronto, Sorin Fedeles, Executive Director, Critical Path Institute (C-Path), Vincent Ko, Founder and Executive Director, KidneyFuture, Christopher Chen, Vice President of Research Programs, PKD Foundation

Category: Conferences | Science, Health and Medicine | Pharmaceuticals

Date and Time: 18th August 2026 at 7:00 am to 20th August 2026 at 5:00 pm